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Enchondromatosis (Ollier disease, Maffucci syndrome) is a rare developmental disorder characterized by
multiple enchondromas. Not much is known about its molecular genetic background. Recently, an activating
mutation in the parathyroid hormone receptor type 1 (PTHR1) gene, c.448C>T (p.R150C), was reported in
two of six patients with enchondromatosis. The mutation is thought to result in upregulation of the IHH/
PTHrP pathway. This is in contrast to previous studies, showing downregulation of this pathway in other
cartilaginous tumors. Therefore, we investigated PTHR1 in enchondromas and chondrosarcomas from 31
enchondromatosis patients from three different European countries, thereby excluding a population bias.
PTHR1 protein expression was studied using immunohistochemistry, revealing normal expression. The
presence of the described PTHR1 mutation was analyzed, using allele-specific oligonucleotide hybridization
confirmed by sequence analysis, in tumors from 26 patients. In addition, 11 patients were screened for other
mutations in the PTHR1 gene by sequence analysis. Using both allele-specific oligonucleotide hybridization and
sequencing, we could neither confirm the previously found mutation nor find any other mutations in the
PTHR1 gene. These results indicate that the PTHR1 gene is not, in contrast to previous suggestions, the culprit
for enchondromatosis. Hum Mutat 24:466–473, 2004. r 2004 Wiley-Liss, Inc.
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INTRODUCTION
Ollier disease (enchondromatosis, MIM# 166000) is a
rare developmental disorder that seems to distribute in a
nonhereditary manner. The syndrome is characterized by
skeletal deformities and multiple enchondromas, often
with unilateral predominance [Ollier, 1900]. Enchon-
dromas are benign cartilaginous lesions, located in the
metaphyseal medulla of bone. The solitary form of
enchondroma is far more common than the rare
occurrence within the context of enchondromatosis.
Maffucci syndrome is a rare variant of enchondroma-
tosis characterized by both multiple enchondromas and
benign hemangiomas [Maffucci, 1881]. Apart from these
two enchondromatosis syndromes, recognized by the
World Health Organization (WHO) [Mertens and Unni,
2002], there are other extremely rare distinct variants
described, such as spondyloenchondromatosis (MIM#
271550) [Chagnon et al., 1985; Halal and Azouz, 1991;
Uhlmann et al., 1998; Kozlowski and Masel, 2002].
Malignant transformation of enchondromas to chon-
drosarcomas occurs in o1% of solitary cases [Mulder
et al., 1993], and 25 to 30% of enchondromatosis cases
[Mulder et al., 1993; McDermott et al., 2001].
Chondrosarcomas can be either conventional central
(83%) or secondary peripheral (17%), with central
chondrosarcomas arising de novo, or as a result of
malignant transformation of an enchondroma [Bertoni
et al., 2002].
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Secondary peripheral chondrosarcomas arise, by its
definition, secondarily within the cartilaginous cap of its
benign precursor, osteochondroma, which is solitary or
occurs in the context of multiple osteochondromas (MO)
syndrome [Bovée and Hogendoorn, 2002]. In contrast to
enchondromatosis, MO demonstrates a clear autosomal
dominant inheritance pattern, caused by EXT1 or EXT2
mutations. EXT mutations are postulated to disturb, via
heparan sulfate proteoglycans, the Indian hedgehog
(IHH)/parathyroid hormone–related peptide (PTHrP)
negative feedback loop within the normal human growth
plate [Bovée and Hogendoorn, 2002; Hogendoorn et al.,
2003], and absence of these signaling molecules has been
demonstrated in osteochondromas [Bovée et al., 2000b].
Three genetic studies have been reported on enchon-
dromatosis. Cytogenetic analysis showed a interstitial
deletion at chromosomal region 1p in one case [Ozisik
et al., 1998], loss of heterozygosity (LOH) at 13q14 and
9p21 and p53 overexpression in chondrosarcoma in
another case [Bovée et al., 2000a], and recently, Hopyan
et al. [2002] described a mutation in the parathyroid
hormone receptor 1 (PTHR1, MIM# 168468), PTHR1
c.448C4T (p.R150C PTHR1), which was found in two
of six patients with Ollier disease, one a germline and the
other probably a somatic mutation. This mutation was
absent in 50 solitary chondrosarcomas and 100 un-
affected individuals [Hopyan et al., 2002]. The single
nucleotide change in PTHR1 codes for an amino acid
change, which results in a constitutively active receptor,
with reduced translocation to the membrane (as shown
by Western blot), reduced PTHrP binding (by cell
transfection), and a decrease in chondrocyte differentia-
tion (PTHR1 p.R150C mouse model). The authors
argued that, by upregulation of IHH/PTHrP signaling,
this leads to the formation of enchondromas [Hopyan
et al., 2002].
It is difficult to perceive that upregulation of IHH/
PTHrP signaling would lead to enchondroma formation,
knowing that downregulation of IHH/PTHrP signaling,
as a result of EXT mutation [McCormick et al., 1999;
Bovée et al., 2000b; Bovée and Hogendoorn, 2002;
Hogendoorn et al., 2003], plays a role in osteochon-
droma formation. We therefore investigated the role of
PTHR1 in enchondromatosis, by studying the expression
of the PTHR1 protein and screening for the specified
p.R150C PTHR1 mutation. In addition, in 11 patients,




In total, 23 enchondromas and 18 chondrosarcomas from 31
patients with enchondromatosis were obtained. The samples were
collected from the files of The Netherlands Committee for Bone
Tumors (three patients; six samples), the Leiden University
Medical Center (nine patients; 14 samples), Rizzoli Orthopedic
Institute, Bologna, Italy (15 patients; 15 samples), and the
Institute of Pathology, University of Bern, Switzerland (four
patients; six samples).
Patient data were obtained by review of clinical charts and
radiographs. Grading was performed according to Evans et al.
[1977]. Patients were included if at least two different sites were
affected by enchondromas and or chondrosarcomas [Mertens and
Unni, 2002]. For patient descriptions, see Table 1. All procedures
were performed according to the local ethical guidelines.
PTHR1 Immunohistochemistry
In 24 of the 31 cases, paraffin blocks were available for
immunohistochemistry. From each patient, one tumor was used.
Sections (4 mm) were stained with the polyclonal PTHR1 antibody
from Babco (Eurogentec, San Diego, CA) in a 1 in 75 dilution,
using a citrate antigen retrieval as previously described [Bovée
et al., 1998]. As a positive control, skin was used, and vessel walls
and osteoblasts served as an internal positive control. Two
independent observers scored the sections.
DNA Isolation
Tumor DNA was isolated from paraffin-embedded (n = 24), as
well as fresh frozen material (n = 12). From 13 patients normal
DNA was also obtained (10 from paraffin, two from frozen tissue,
and one from blood). The tumor percentage as determined by
hematoxylin and eosin stained slides was at least 70%. DNA from
paraffin-embedded material was isolated as described earlier [De
Leeuw et al., 2000]. Some samples were microdissected to enrich
for tumor percentage or to obtain normal DNA. Samples isolated
from paraffin-embedded material with a low DNA concentration
were concentrated using the DNA Clean and Concentrator kit
(Zymo Research, Orange, CA). DNA from fresh frozen material
was isolated using a wizard genomic DNA purification kit
(Promega, Madison, WI), and DNA of blood was isolated using
a salting out procedure according to Miller and Polesky [1988].
R150C PTHR1PCR
Genomic DNA of the PTHR1 gene (NM_000316.2) containing
the position of the p.R150C PTHR1 mutation was amplified using
the PCR primers 50-TGACACACTCGCTGTAGTTGG-30
(PTHR1-F) and 50-TTGGAGCTAGGGGTTCAGTG-30
(PTHR1-R), generating a 154-bp product. As a positive control,
DNA isolated from a normal placenta was used, both to serve as a
control for the PCR and as a wild-type control for the allele-
specific oligonucleotide (ASO) hybridization.
Construction of theMutant Sequence
A plasmid containing the PTHR1 fragment with the c to t
substitution (c.448C>T) was constructed using mutation specific
PCR [Ho et al., 1989]. Detailed description of the construction
can be obtained on request.
ASOHybridization
For detection of the p.R150C PTHR1 mutation, PCR fragments
of tumor and control DNA were electrophoresed on a 2% agarose
gel and blotted to nylon membranes (Hybondt-N+; Amersham
Biosciences, Piscataway, NJ) as described earlier [Devilee et al.,
1991]. A separate blot was made with a dilution series of a mix of
wild-type and constructed mutant PCR products in different
concentrations. The blots were hybridized with a-32P oligonucleo-
tides specific for wild-type (50-ACGCTGTGACCGCAATGGCA-
30) or mutant (50-ACGCTGTGACTGCAATGGCA-30). Oligo-
nucleotides were labeled in 6 ml containing 20 pmol oligonucleo-
tide, 1ml [a-32P] ATP (10 mCi), 1 kinase buffer (70 mM Tris,
pH 7.6; 10 mM MgCl2), 9 units T4 PNK kinase (USB; US
Biochemicals, Cleveland, OH) for 1 hr at 371C and 5 min at 651C.
The blot was hybridized overnight with a hybridization mix
containing 0.5 M NaHPO4/NaH2PO4 (pH 7.0), 7% SDS at
651C (wild-type) and 681C (mutant). After washing the filters



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































with 1 SSC/0.5% SDS, they were exposed to a Phosphor Imager
screen (Amersham Biosciences, Piscataway, NJ).
The blot containing the samples was first hybridized with the
mutant probe, then stripped at 681C with 0.1 SSC/0.5% SDS
and subsequently hybridized with wild-type probe. Complete
stripping of the blot was checked by phosphor imaging.
Signal intensities were scored as peak heights as detected by
ImageQuant (Molecular Dynamics, Sunnyvale, CA).
Sequencing for the p.R150C PTHR1Mutation
For 19 cases, the absence of the mutation, as detected by ASO
hybridization, was confirmed by sequence analysis of the PCR
fragment, using the forward and/or reverse PCR primer. Among
the samples chosen were those tumor samples with a relative signal
comparable and lower to the wild-type sample. The PCR products
of these samples were purified using QIAGEN QIAquick PCR
Purification Kit (QIAGEN, Germantown, MD) prior to sequen-
cing.
Sequencing was performed using the ABI PRISMs Big Dye
Terminators v. 2.0 Cycle Sequencing Kit (Applied Biosystems,
Foster City, CA). Samples were run on an ABI 3700 Genetic
Analyzer (Applied Biosystems).
Sequencing of the Entire PTHR1Gene
Fresh frozen tissue to obtain high molecular weight DNA was
available for 11 patients affected by Ollier disease; five of which
were not analyzed by the ASO hybridization. Genomic DNA was
subjected to direct sequencing for the PTHR1 gene
(NM_000316.2). Patient data are resumed in Table 1 (Patients
17, 19, 21, 22, 24, 25, and 27–31). All coding exons, including
exon–intron boundaries, were amplified according to primers
described by Schipani et al. [1995] and with additional primers
described in Table 2, based on the sequences U22401–U22409.
RESULTS
Patient Data
In total, 41 tumors from 31 patients with enchon-
dromatosis were collected. Clinical details of all patients
are shown in Table 1.
PTHR1 Immunohistochemistry
Staining results are shown in Table 1. Due to loss of
attachment of the tissue section from the slide, as a result
of the antigen retrieval procedure, 10 of the 24 samples
could not be evaluated. Eight out of 14 samples were
scored as positive for the presence of PTHR1 protein,
five demonstrated only weak positivity, while one tumor
was completely negative with a positive internal control.
The staining was mainly found in the nucleus, but
cytoplasmic staining was also found (Fig. 1). The results
were similar to those obtained for 20 sporadic chon-
drosarcoma cases [Bovée et al., 2000b].
ASOHybridization: p.R150C PTHR1Mutation
Of the 36 samples from 26 patients (Patients 1–26), 33
samples resulted in a PCR product of the expected size,
though the amount of final PCR product varied
considerably. The three samples failing were DNA
samples isolated from paraffin-embedded tissues, one
failing normal and tumor sample, the third only failing
the tumor sample.
Blots containing PCR products from the PTHR1
fragment were hybridized for the mutant sequence,
resulting in strong hybridization signals with intensities
that decreased linear according to a dilution series of
PCR products containing the constructed mutant as
shown in Figure 2a. However, we did see cross-
hybridization of the mutant probe with wild-type PCR
products that could not be overcome by more stringent
hybridization (Fig. 2a). The wild-type probe showed
strong signals with the wild-type control (placental DNA
from a healthy donor) and samples, but no cross-
hybridization with the constructed mutant (Fig. 2b).
In the dilution experiment, the mutant sequence
could be detected in a background of wild-type sequence
containing 90% wild-type PCR product and 10%
constructed mutant PCR product. Using this experi-
ment, a cutoff value for the probes was determined
(0.20). The signal threshold of the mutant oligonucleo-
tide was defined as the strongest signal obtained by
phosphor imager analysis, for the wild-type control
fragment with the mutant oligonucleotide divided by
the signal of the wild-type oligonucleotide for that
sample. All patient samples showed a signal for the
mutant oligonucleotide/wild-type oligonucleotide ratio
below this threshold, ranging from 0.03 to 0.19. In
contrast, the signal of constructed mutant, even in a 1 in
10 dilution, was above this threshold (value 0.26).
Sequencing for the p.R150C PTHR1Mutation
A total of 19 samples were selected for sequencing to
confirm the results found in the ASO hybridization. All
TABLE 2. Sequence of theAdditional DesignedNucleotide Primers
of Each Exon ofPTHR1
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19 samples showed the wild-type sequence (reviewed but
not shown).
Sequencing of the Entire PTHR1Gene
From the 11 patients for whom the whole PTHR1
gene was sequenced, all PCR reactions resulted in
sequencing products. No mutations and/or polymorph-
isms were detected in the coding exons of the gene.
DISCUSSION
The PTHR1 protein is important in chondrogenesis
and skeletogenesis and is involved in the IHH/PTHrP
feedback loop present in the growth plate [Lanske et al.,
1996; Van der Eerden et al., 2000; de Crombrugghe et al.,
2001; Hogendoorn et al., 2003]. IHH binds to its
receptor Patched (Ptc) after diffusion, presumably under
mediation of heparan sulfate proteoglycans (HSPG) of
which the biosynthesis is mediated by EXT. The binding
results in PTHrP expression, which then binds to PTHR1
in the late proliferating zone [Erlebacher et al., 1995],
resulting in upregulation of Bcl-2 [Amling et al., 1997;
Van der Eerden et al., 2000]. This signaling regulates the
pace of chondrocyte differentiation by delaying the
progression of chondrocytes towards the hypertrophic
zone, allowing longitudinal bone growth [Van der Eerden
et al., 2000].
Deregulation of this feedback loop can result in many
different syndromes. For instance, in patients with
Blomstrand chondrodysplasia (MIM# 215045), inacti-
vating mutations have been identified in PTHR1
[Gardella and Juppner, 2001], resulting in accelerated
chondrocyte differentiation and premature ossification
[Leroy et al., 1996]. In contrast, constitutive active
PTHR1 mutations have been identified in patients with
Jansen metaphyseal chondrodysplasia (MIM# 156400)
[Gardella and Juppner, 2001]. These patients have a
delay in chondrocyte differentiation, in vascular inva-
sion, and a reduction or absence of mineralization of
bone elements that are formed through the endochon-
dral process [Schipani et al., 1997]. This syndrome shares
some radiographical and histological features with
enchondromatosis, like the presence of radiolucent areas
containing noncalcified cartilage [Jaffe, 1972].
In patients with MO mutations in the EXT genes are
found, postulated to lead to a downregulation of the
IHH/PTHrP pathway [McCormick et al., 1999; Bovée
and Hogendoorn, 2002]. Indeed, in osteochondromas,
that are histologically comparable to the human growth
plate, absence of IHH/PTHrP signaling was demon-
strated [Bovée et al., 2000b]. Upon malignant transfor-
mation of osteochondromas, upregulation of PTHrP and
Bcl-2 was detected, and this was also found during
progression of low- toward high-grade conventional
central chondrosarcomas.
Surprisingly, the p.R150C mutation is described to
lead to an upregulation of IHH [Hopyan et al., 2002]. It
is difficult to understand that both upregulation (in
enchondromatosis) and downregulation (in MO) of the
same IHH/PTHrP pathway would cause benign cartila-
ginous tumors. We therefore wanted to further investi-
gate PTHR1 in a large series of enchondromatosis
patients. We looked at the PTHR1 protein expression
in 14 patients with enchondromatosis, revealing normal
expression in 13 cases. Three of five weakly-staining
samples originated from young patients (ages 6, 15, and
FIGURE 1. Immunohistochemical staining for the PTHR1 protein. Sample 22.1, an enchondroma of the phalanx, showing positive
PTHR1 expression in both nucleus and cytoplasm of tumor cells. The endothelial cells, serving as an internal control, also
show PTHR1expression. A:50. B:100. [Color ¢gure can be viewed in the online issue, which is available at www.interscience.
wiley.com.]
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23 years). This suggests that there may be an age-related
expression of PTHR1.
The mutation described by Hopyan et al. [2002] in
two of six (33%) enchondromatosis patients was not
found in the 31 enchondromatosis patients that were the
subject of this article. Sequencing of all exons, including
exon–intron boundaries, of the PTHR1 gene in 11 of
these patients also did not reveal any other mutations.
The possible presence of an intronic splice mutation,
located outside the sequenced products, is not likely
since this would most probably lead to inactivation of the
PTHR1 protein, as seen in Blomstrand chondrodysplasia
[Zhang et al., 1998; Jobert et al., 1998], and not to a
receptor with increased signaling, as was described by
Hopyan et al. [2002]. This indicates that the PTHR1
gene is not involved in Ollier disease and Maffucci
syndrome in our large multinational series. A possible
explanation for this discrepancy could be that the
p.R150C mutation described by Hopyan et al. [2002] is
specific for the Canadian population, i.e., a founder
mutation.
Technically, one could argue that the level of
contamination with normal tissue in our tumor samples
is just too high for detection of somatic mutations by
sequence analysis (in our samples the tumor percentage
was at least 70%). However, the detection level for the
p.R150C mutation using ASO hybridization is high
enough to detect even those cases in which the mutated
sequence is present in only 10% of the total sample as
shown by the dilution experiment. Thus, with the
mutation described by Hopyan et al. [2002] as being
heterozygous, we should have been able to detect the
mutation if it was present.
Another explanation for the discrepancy between the
results of Hopyan et al. [2002] and our results may be
found in the exact definition of the clinical syndrome,
the classification of which is confusing. Enchondroma-
tosis can be divided using several subclassifications
[Halal and Azouz, 1991; Uhlmann et al., 1998;
Kozlowski and Masel, 2002]. The two most important
ones are Ollier disease and Maffucci syndrome, both
accepted by the WHO [Mertens and Unni, 2002].
FIGURE 2. ASOhybridization of the samples with labeled c-32Pmutant andwild-type oligonucleotides. A: Blot of ASO hybridization
with mutant oligonucleotide. B: Blot of ASO hybridization with wild-type oligonucleotide, showing the same samples as seen in A.
constr mut, constructedmutant;wt,wild type.
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Extremely rare is spondyloenchondromatosis, which was
described to be autosomal recessive. Its radiographic
features include irregularly distributed, mostly discrete
enchondromas of long tubular bones and generalized
severe platyspondyly with mild or no involvement of
hands and feet [Schorr et al., 1976; Halal and Azouz,
1991]. Generalized enchondromatosis, with patients
having platyspondyly and metaphyseal manifestations of
enchondromatosis with severe involvement of the hands
and feet, has also been described [Spranger et al., 1978;
Halal and Azouz, 1991].
If the patient carrying the germline p.R150C PTHR1
mutation [Hopyan et al., 2002], belongs to one of these
rare subclasses of enchondromatosis instead of having
Ollier disease, this mutation may be specific for this rare
variant of enchondromatosis. Hopyan et al. [2002]
describe that one of the two patients having the
p.R150C PTHR1 mutation inherited the mutation from
his father, who had short statue, similar to a patient
described by Halal and Azouz [1991] who was diagnosed
with ‘‘generalized enchondromatosis,’’ and following an
autosomal recessive inheritance pattern. Our population
consisted strictly of patients with Ollier disease or
Maffucci syndrome, lacking platyspondyly after reviewing
their clinical charts and radiographs.
In conclusion, in our large, well-characterized, multi-
national group of enchondromatosis patients, we cannot
confirm the involvement of mutations in the PTHR1
gene, indicating that PTHR1 is not causative for
enchondromatosis in contrast to previous reports.
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